Eli Lilly launches its blockbuster weight loss drug Mounjaro in India

Milind Deora slams weight-loss drug Mounjaro's launch, calls for higher sugar taxes

Rajya Sabha member Milind Deora has criticised the launch of Mounjaro in India. The weight-loss drug, developed by US-based Eli Lilly, is a weekly injectable medicine that costs Rs 3,500 for the 2.5 mg vial.

Eli Lilly's weight loss drug Mounjaro launched in India; check prices, how it works

Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors which eventually help with obesity, overweight and type 2 diabetes. Price of Mounjaro in India According to the company, the injection is s…

Eli Lilly launches its blockbuster weight loss drug Mounjaro in India

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, would cost patients between ₹14,000 to ₹17,500 monthly.

Rosie O’Donnell finds her new clothing size ‘completely shocking’ after losing weight on Mounjaro

Rosie O'Donnell said on TikTok that she's been taking Mounjaro to treat her diabetes and has also lost weight.

Blockbuster weight-loss drug Mounjaro comes to India: How does it work?

Mounjaro, now launched in India, is the brand name of the drug called tirzepatide. Like its competitors Ozempic and Wegovy (brand names for the drug semaglutide), it is an injectable that needs to be used once a week. Experts say Mounjaro, which works by binding and activating two receptors – glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)  – has shown incredible results when paired with diet and exercise w…

Fat-busting drug Mounjaro launched in India. Here's how much it will cost

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, it has since become a global blockbuster.